Summary:
A multicenter, randomized, double-blind, placebo-controlled 8 week study to evaluate the safety and efficacy of Nebivolol and Valsartan given as a fixed-dose combination in patients with stage 1 or stage 2 essential Hypertension.
Qualified Participants Must:
• Have Hypertension
•
Be willing to comply with study protocols
Qualified Participants May Receive:
$50 dollars per visit (if randomized), free study medication
and free study related healthcare.